XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

BACKGROUND: We report updated overall survival (OS) data from study NO16966, which compared capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX4) as first-line therapy in metastatic colorectal cancer. METHODS: NO16966 was a randomised, two-arm, non-inferiori...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassidy, J, Clarke, S, Díaz-Rubio, E, Scheithauer, W, Figer, A, Wong, R, Koski, S, Rittweger, K, Gilberg, F, Saltz, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137415/
https://www.ncbi.nlm.nih.gov/pubmed/21673685
http://dx.doi.org/10.1038/bjc.2011.201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137415/
https://www.ncbi.nlm.nih.gov/pubmed/21673685
http://dx.doi.org/10.1038/bjc.2011.201

Ejemplares similares